Insider Buying: FocalTherics (NASDAQ:FOCL) Director Purchases $47,500.00 in Stock

FocalTherics (NASDAQ:FOCL) Director Joshua Levine purchased 10,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 45,000 shares of the company’s stock, valued at $213,750. This represents a 28.57% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

FocalTherics Price Performance

FocalTherics stock opened at $4.36 on Thursday. The stock has a market capitalization of $163.41 million, a PE ratio of -4.23 and a beta of -0.04. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The firm has a 50 day simple moving average of $5.37. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 0.99.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The business had revenue of $13.20 million for the quarter. On average, equities research analysts anticipate that FocalTherics will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the fourth quarter worth about $2,623,000. Leonteq Securities AG purchased a new stake in FocalTherics during the 4th quarter valued at about $313,000. Rock Springs Capital Management LP raised its holdings in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares during the last quarter. Kovack Advisors Inc. acquired a new stake in FocalTherics in the 4th quarter valued at about $53,000. Finally, Lido Advisors LLC purchased a new position in FocalTherics in the 1st quarter worth approximately $40,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on FOCL. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a report on Friday, August 14th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, FocalTherics has a consensus rating of “Hold” and a consensus price target of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.